Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

Bamias, Aristotelis; Gibbs, Emma; Lee, Chee Khoon; Davies, Lucy; Dimopoulos, Meletios Α.; Zagouri, Flora; Veillard, Anne-Sophie; Kosse, Jens; Santaballa, Ana; Mirza, Mansoor Raza; Tabaro, Gianna; Vergote, Ignace; Bloemendal, Haiko J.; Lykka, Maria; Floquet, Anne; Gebski, Val; Pujade-Lauraine, Éric

doi:10.1093/annonc/mdx228

Cited by 47 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 113 patients with baseline ascites 17% required paracentesis in the control arm vs. 2% in the BEV arm and PROMs for GI symptoms were better with BEV [28]. OS was not significantly different in the context of 40% crossover but a recent exploratory analysis suggestive a survival advantage in those who received BEV during or after the study [29]. Adverse events were consistent with previous studies.…”

Section: Bevacizumabsupporting

confidence: 83%

Novel Systemic Treatments in High Grade Ovarian Cancer

Samani¹,

Chan²,

Krell³

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

Most patients with ovarian cancer present at an advanced stage and are never cured. To improve outcomes a variety of novel systemic strategies are being developed. Traditional cytotoxic chemotherapy is being optimised, anti-angiogenic strategies are already in the clinic and several PARP inhibitors have gained regulatory approval. In addition, immunotherapy is showing promise and novel targeted strategies including against folate receptor alpha are also generating excitement. As our therapeutic choice increases, a challenge will be how to best utilize the options available. Here we discuss recently established and other emerging therapies with a focus on key concepts rather than detailed synopses of trial designs and outcomes.

show abstract

Section: Bevacizumabsupporting

confidence: 83%

Novel Systemic Treatments in High Grade Ovarian Cancer

Samani¹,

Chan²,

Krell³

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

show abstract

“…A phase III randomised trial of patients with platinum resistant ovarian cancer compared chemotherapy with or without bevacizumab (AURELIA, NCT00976911). Increased overall survival ( p = 0.001) was found in patients receiving bevacizumab compared to those receiving chemotherapy alone ( n = 110) [ 287 ]. However, a phase III randomised trial of bevacizumab with chemotherapy in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer (NCT00262847) found no survival differences for patients receiving bevacizumab compared to those receiving chemotherapy alone [ 288 ].…”

Section: Agents and Strategies For Cancer Immunotherapymentioning

confidence: 99%

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Macpherson

Barry

Ricciardelli

et al. 2020

JCM

View full text Add to dashboard Cite

Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.

show abstract

“…Platinum‐resistant disease, defined as relapse within 6 months, is usually treated with nonplatinum‐based chemotherapy regimens or with experimental agents on clinical trials. Clinical response to chemotherapy decreases with sequential treatments, and in platinum‐resistant disease, the maximal response rate is only 30% to 40%, with a median OS of 12 months Type I epithelial cancersDespite their known resistance to platinum‐containing chemotherapy, treatment of type I cancers is still based on the more common type II tumors, with debulking surgery and platinum‐containing chemotherapy.…”

Section: Nonepithelial Cancersmentioning

confidence: 99%

Section: Nonepithelial Cancersmentioning

confidence: 99%

Ovarian cancer in adolescents and young adults

Lockley

Stoneham

Olson

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

The diagnosis of ovarian cancer in adolescents and young adults is always challenging. Many issues exist, and most important of these may be access to care with an appropriate provider. A range of histologies occur in the ovaries, and their frequency changes markedly as patients progress from adolescence to young adulthood. The very curable germ cell tumors of adolescence slowly give way to aggressive carcinomas, which require a different treatment approach. Special consideration is needed for treatment of toxicity. In an ideal world, centers consisting of pediatric, medical, and gynecological oncologists may be the most appropriate to care for these complex and diverse patients.

show abstract

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

Cited by 47 publications

References 19 publications

Novel Systemic Treatments in High Grade Ovarian Cancer

Novel Systemic Treatments in High Grade Ovarian Cancer

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Ovarian cancer in adolescents and young adults

Contact Info

Product

Resources

About